BIO-PREDISC-TIA SWISS Cohort Study

D

Dr. med. Carlo Cereda

Status

Completed

Conditions

Cerebrovascular Disease, Ischemic Stroke

Study type

Observational

Funder types

Other

Identifiers

NCT03994003
EOC.NSISU.4.12.99

Details and patient eligibility

About

This research project aims at contributing to improve TIA diagnosis and management by using PREDISC scores and specific biomarkers thought to have elevated levels in TIA patients. A swift and accurate TIA diagnosis allows starting treatment of the patient adequately and shortly after the event. The shorter the time between the event and treatment onset, the better the outcome. This approach will be an important step forward in TIA diagnosis and management, similarly to acute coronary syndrome as discussed above.

Enrollment

64 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with suspected TIA (defined as the acute onset of focal neurological symptoms lasting <24 h and presumed to be caused by brain ischemia at the time of referral) within 48 h of symptoms onset.

  • At least 18 years old.
  • Having given their Informed Consent.

Exclusion criteria

· Patients with ocular TIA (Amaurosis fugax).

  • Patients that still have neurological deficits at the moment of inclusion.
  • Contraindication to perform MRI.
  • For women: pregnancy.

Trial contacts and locations

0

Loading...

Central trial contact

Carlo Cereda, MD; Concetta Manno, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems